NCT05228262 Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis
| NCT ID | NCT05228262 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Clermont-Ferrand |
| Condition | Osteoporosis, Postmenopausal |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2022-02-15 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2022-02-15 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to follow a cohort of osteoporotic patients treated with anti-osteoporotic drugs and to evaluate the impact of these treatments on the osteoporosis-cardiovascular-sarcopenia triad and on pain.
Eligibility Criteria
Inclusion Criteria: * Women aged 50 years or older with postmenopausal osteoporosis, whether fractured or not, requiring initiation of treatment with antiosteoporotic drugs (bisphosphonates, raloxifene, teriparatide, denosumab and others to come for this indication, including romosozumab), either orally or by injection, as part of their care and management. * Able to give informed consent to participate in research. * Affiliation to a Social Security system. Exclusion Criteria: * Patient with chronic renal failure, defined as glomerular filtration rate \< 30 mL.min-1 estimated by CKD-EPI. * Patient with a medical and/or surgical history deemed by the investigator or his/her representative to be incompatible with the trial. * Patient under legal protection or deprived of liberty. * Refusal to participate.
Contact & Investigator
Marie-Eva Pickering
PRINCIPAL INVESTIGATOR
University Hospital, Clermont-Ferrand
Frequently Asked Questions
Who can join the NCT05228262 clinical trial?
This trial is open to female participants only, aged 50 Years or older, studying Osteoporosis, Postmenopausal. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05228262 currently recruiting?
Yes, NCT05228262 is actively recruiting participants. Contact the research team at promo_interne_drci@chu-clermontferrand.fr for enrollment information.
Where is the NCT05228262 trial being conducted?
This trial is being conducted at Clermont-Ferrand, France.
Who is sponsoring the NCT05228262 clinical trial?
NCT05228262 is sponsored by University Hospital, Clermont-Ferrand. The principal investigator is Marie-Eva Pickering at University Hospital, Clermont-Ferrand. The trial plans to enroll 150 participants.